APA (7th ed.) Citation

D, S., EM, L., C, D. d. G., J, G., M, G., E, B., & F, V. (2026). Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination among US adults aged 18-49 years at increased risk for severe RSV disease. Vaccine, 88, 128770. https://doi.org/10.1016/j.vaccine.2026.128770

Chicago Style (17th ed.) Citation

D, Singer, La EM, Dubois de Gennes C, Graham J, Grace M, Biundo E, and Verelst F. "Public Health Impact and Cost-effectiveness of Adjuvanted RSVPreF3 Vaccination Among US Adults Aged 18-49 years at Increased Risk for Severe RSV Disease." Vaccine 88 (2026): 128770. https://doi.org/10.1016/j.vaccine.2026.128770.

MLA (9th ed.) Citation

D, Singer, et al. "Public Health Impact and Cost-effectiveness of Adjuvanted RSVPreF3 Vaccination Among US Adults Aged 18-49 years at Increased Risk for Severe RSV Disease." Vaccine, vol. 88, 2026, p. 128770, https://doi.org/10.1016/j.vaccine.2026.128770.